Scarica l'app Stockscreener
9.44
7.15%
0.63
Turn Therapeutics Inc Borsa (TTRX) Ultime notizie
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout - sharewise.com
Turn Therapeutics’ stock jumps on AD data and trial expansion - MSN
Turn Therapeutics Reaches US$229m Market Cap Benefiting Insider Stock Buying - Moomoo
Turn Therapeutics (TTRX) Study update Summary - Quartr
TTRX: GX-03 phase II interim data show robust efficacy and safety, with stage two now optimized - TradingView
TTRX: GX-03 phase II interim data show strong efficacy and safety, with phase III targeted for mid-2027 - TradingView
Why Is Turn Therapeutics Stock Trading Higher Today? - Benzinga
AD Pipeline Watch: Turn Therapeutics Expands Phase 2 AD Trial After GX-03 Shows Broad Efficacy in Interim Analysis - The Dermatology Digest
TTRX: GX-03 demonstrates robust efficacy and safety in Phase 2 atopic dermatitis interim analysis - TradingView
TTRX: GX-03 showed robust efficacy in atopic dermatitis, leading to an expanded Phase 2 trial design - TradingView
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - BioSpace
Turn Therapeutics stock rises on expanded dermatitis trial By Investing.com - Investing.com UK
Turn Therapeutics stock rises on expanded dermatitis trial - Investing.com
Turn Therapeutics expands phase 2 atopic dermatitis trial - Investing.com
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis - marketscreener.com
Turn Therapeutics expands phase 2 atopic dermatitis trial By Investing.com - Investing.com Nigeria
EDGAR Filing Documents for 0001213900-26-075757 - SEC.gov
Turn Therapeutics finalizes expanded Stage 2 design for GX-03 Phase 2 in atopic dermatitis - TradingView
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Turn Therapeutics (TTRX) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - BioSpace
Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data - Moomoo
Stocks to Watch: Rivian, Turn Therapeutics, Globavend - Moomoo
If You Invested $1,000 in Turn Therapeutics Inc (TTRX) - Stock Titan
Turn Therapeutics Company Profile & Introduction - Moomoo
TTRX Q1 2026 Earnings: Narrow EPS Miss as Pre-Revenue Biotech Focuses on Pipeline ProgressEarnings Revision Report - dars.gov.et
TTRXTurn Therapeutics Inc Volatility & Greeks - Finviz
Turn Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Turn Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$217m - Sahm
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - The National Law Review
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to Russell 3000E Growth Benchmark - marketscreener.com
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to Russell Microcap Index - marketscreener.com
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics (TTRX) Short Interest & Short Float | Updated Jun 2026 $TTRX - MarketBeat
Turn Therapeutics Inc. Actuals & Estimates (NASDAQ:TTRX) - TradingView
TTRX Q1 2026 Earnings: Narrow Miss on EPS as Stock RisesInvestor Earnings Call - dars.gov.et
Strength seen in Intellia Therapeutics (NTLA): Can its 23.2% jump turn into more strength? - MSN
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Ord Shs (TTRX) Institutional Confidence - TradingKey
Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads - StocksToTrade
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo Finance
Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Slight EPS Miss Amid Pre-Revenue Stage; Shares Rise - newsline.com
First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
TTRX Q1 2026 Earnings: Narrow EPS Miss Highlights Ongoing Development PhaseRevenue Miss Report - newsline.com
TTRX Q1 2026 Earnings: Slight EPS Miss as Company Reports Loss Per Share of -$0.026Quarterly Profit Report - newsline.com
Turn Therapeutics (TTRX) Surges 9.4%: Key Levels and What Could Drive Further MomentumBPI Reversal - dars.gov.et
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down - Yahoo Finance
TTRX Q1 2026 Earnings: EPS Misses Estimates, Shares Fall 4.6%Profit Margin Analysis - newsline.com
2 Software Stocks to Keep an Eye On and 1 We Turn Down - Yahoo Finance
2 Financials Stocks to Target This Week and 1 We Turn Down - Yahoo Finance
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):